
James S Ware

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5320212/publications.pdf Version: 2024-02-01



IAMES S WADE

#	Article	IF	CITATIONS
1	Analysis of protein-coding genetic variation in 60,706 humans. Nature, 2016, 536, 285-291.	13.7	9,051
2	The mutational constraint spectrum quantified from variation in 141,456 humans. Nature, 2020, 581, 434-443.	13.7	6,140
3	De novo mutations in congenital heart disease with neurodevelopmental and other congenital anomalies. Science, 2015, 350, 1262-1266.	6.0	646
4	Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. Genetics in Medicine, 2017, 19, 192-203.	1.1	585
5	Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy. Circulation, 2018, 138, 1387-1398.	1.6	468
6	Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. New England Journal of Medicine, 2016, 374, 233-241.	13.9	432
7	Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet, The, 2019, 393, 61-73.	6.3	379
8	Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease. Science Translational Medicine, 2015, 7, 270ra6.	5.8	375
9	Using high-resolution variant frequencies to empower clinical genome interpretation. Genetics in Medicine, 2017, 19, 1151-1158.	1.1	355
10	Adaptation and validation of the ACMG/AMP variant classification framework for MYH7-associated inherited cardiomyopathies: recommendations by ClinGen's Inherited Cardiomyopathy Expert Panel. Genetics in Medicine, 2018, 20, 351-359.	1,1	283
11	Reappraisal of Reported Genes for Sudden Arrhythmic Death. Circulation, 2018, 138, 1195-1205.	1.6	271
12	Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes. Circulation Genomic and Precision Medicine, 2019, 12, e002460.	1.6	267
13	Titin-truncating variants affect heart function in disease cohorts and the general population. Nature Genetics, 2017, 49, 46-53.	9.4	255
14	An International, Multicentered, Evidence-Based Reappraisal of Genes Reported to Cause Congenital Long QT Syndrome. Circulation, 2020, 141, 418-428.	1.6	238
15	Utility of Post-Mortem Genetic Testing in Cases of Sudden Arrhythmic Death Syndrome. Journal of the American College of Cardiology, 2017, 69, 2134-2145.	1.2	219
16	Evidence-Based Assessment of Genes in Dilated Cardiomyopathy. Circulation, 2021, 144, 7-19.	1.6	213
17	Genetic Variants Associated With Cancer Therapy–Induced Cardiomyopathy. Circulation, 2019, 140, 31-41.	1.6	195
18	Genetic Etiology for Alcohol-Induced Cardiac Toxicity. Journal of the American College of Cardiology, 2018, 71, 2293-2302.	1.2	182

#	Article	IF	CITATIONS
19	Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity. Nature Genetics, 2021, 53, 135-142.	9.4	165
20	Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. Nature Genetics, 2021, 53, 128-134.	9.4	155
21	Effects of myosin variants on interacting-heads motif explain distinct hypertrophic and dilated cardiomyopathy phenotypes. ELife, 2017, 6, .	2.8	153
22	Reevaluating the Genetic Contribution of Monogenic Dilated Cardiomyopathy. Circulation, 2020, 141, 387-398.	1.6	148
23	Defining the genetic architecture of hypertrophic cardiomyopathy: re-evaluating the role of non-sarcomeric genes. European Heart Journal, 2017, 38, ehw603.	1.0	142
24	Endonuclease G is a novel determinant of cardiac hypertrophy and mitochondrial function. Nature, 2011, 478, 114-118.	13.7	135
25	Sudden Death and Left Ventricular Involvement in Arrhythmogenic Cardiomyopathy. Circulation, 2019, 139, 1786-1797.	1.6	122
26	Role of titin in cardiomyopathy: from DNA variants to patient stratification. Nature Reviews Cardiology, 2018, 15, 241-252.	6.1	115
27	Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction. Circulation, 2020, 141, 1371-1383.	1.6	108
28	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases. Europace, 2022, 24, 1307-1367.	0.7	108
29	Characterising the loss-of-function impact of 5' untranslated region variants in 15,708 individuals. Nature Communications, 2020, 11, 2523.	5.8	99
30	Congenital Titinopathy: Comprehensive characterization and pathogenic insights. Annals of Neurology, 2018, 83, 1105-1124.	2.8	93
31	Dilated Cardiomyopathy DueÂtoÂBLC2-Associated AthanogeneÂ3Â(BAC3)ÂMutations. Journal of the American College of Cardiology, 2018, 72, 2471-2481.	1.2	93
32	Quantitative approaches to variant classification increase the yield and precision of genetic testing in Mendelian diseases: the case of hypertrophic cardiomyopathy. Genome Medicine, 2019, 11, 5.	3.6	90
33	Phenotype and Clinical Outcomes of TitinÂCardiomyopathy. Journal of the American College of Cardiology, 2017, 70, 2264-2274.	1.2	86
34	Genetic and functional insights into the fractal structure of the heart. Nature, 2020, 584, 589-594.	13.7	86
35	Interpreting <i>de novo</i> Variation in Human Disease Using denovolyzeR. Current Protocols in Human Genetics, 2015, 87, 7.25.1-7.25.15.	3.5	84
36	Development of a Comprehensive Sequencing Assay for Inherited Cardiac Condition Genes. Journal of Cardiovascular Translational Research, 2016, 9, 3-11.	1.1	80

#	Article	IF	CITATIONS
37	The effect of LRRK2 loss-of-function variants in humans. Nature Medicine, 2020, 26, 869-877.	15.2	79
38	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the State of Genetic Testing for Cardiac Diseases. Heart Rhythm, 2022, 19, e1-e60.	0.3	78
39	CardioClassifier: disease- and gene-specific computational decision support for clinical genome interpretation. Genetics in Medicine, 2018, 20, 1246-1254.	1.1	75
40	Natural genetic variation of the cardiac transcriptome in non-diseased donors and patients with dilated cardiomyopathy. Genome Biology, 2017, 18, 170.	3.8	70
41	Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy. European Heart Journal, 2021, 42, 1988-1996.	1.0	69
42	Phenotypic and pharmacogenetic evaluation of patients with thiazide-induced hyponatremia. Journal of Clinical Investigation, 2017, 127, 3367-3374.	3.9	58
43	Enhancing rare variant interpretation in inherited arrhythmias through quantitative analysis of consortium disease cohorts and population controls. Genetics in Medicine, 2021, 23, 47-58.	1.1	57
44	Evaluation of gene validity for CPVT and short QT syndrome in sudden arrhythmic death. European Heart Journal, 2022, 43, 1500-1510.	1.0	57
45	Truncating Variants in Titin Independently Predict Early Arrhythmias in Patients With Dilated Cardiomyopathy. Journal of the American College of Cardiology, 2017, 69, 2466-2468.	1.2	56
46	The Gene Curation Coalition: A global effort to harmonize gene–disease evidence resources. Genetics in Medicine, 2022, 24, 1732-1742.	1.1	56
47	Phenotypic Expression and Outcomes in Individuals With Rare Genetic Variants of Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2021, 78, 1097-1110.	1.2	55
48	Towards Clinical Molecular Diagnosis of Inherited Cardiac Conditions: A Comparison of Bench-Top Genome DNA Sequencers. PLoS ONE, 2013, 8, e67744.	1.1	51
49	Loss of RNA expression and allele-specific expression associated with congenital heart disease. Nature Communications, 2016, 7, 12824.	5.8	51
50	Detection of mutations in <i>KLHL3</i> and <i>CUL3</i> in families with FHHt (familial hyperkalaemic) Tj ETQqC) 0 0 rgBT 1.8	/Overlock 10
51	Temporal Trend of Age at Diagnosis in Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2020, 13, e007230.	1.6	48
52	Spatial and Functional Distribution of <i>MYBPC3</i> Pathogenic Variants and Clinical Outcomes in Patients With Hypertrophic Cardiomyopathy. Circulation Genomic and Precision Medicine, 2020, 13, 396-405.	1.6	47
53	Next generation sequencing for clinical diagnostics and personalised medicine: implications for the next generation cardiologist. Heart, 2012, 98, 276-281.	1.2	46

⁵⁴Clinical Features and Natural History of PRKAG2 Variant Cardiac Glycogenosis. Journal of the
American College of Cardiology, 2020, 76, 186-197.1.245

#	Article	IF	CITATIONS
55	Addendum: The mutational constraint spectrum quantified from variation in 141,456 humans. Nature, 2021, 597, E3-E4.	13.7	45
56	Systematic large-scale assessment of the genetic architecture of left ventricular noncompaction reveals diverse etiologies. Genetics in Medicine, 2021, 23, 856-864.	1,1	45
57	Paralogous annotation of disease-causing variants in long QT syndrome genes. Human Mutation, 2012, 33, 1188-1191.	1.1	44
58	Paralogue annotation identifies novel pathogenic variants in patients with Brugada syndrome and catecholaminergic polymorphic ventricular tachycardia. Journal of Medical Genetics, 2014, 51, 35-44.	1.5	44
59	Analysis of 51 proposed hypertrophic cardiomyopathy genes from genome sequencing data in sarcomere negative cases has negligible diagnostic yield. Genetics in Medicine, 2019, 21, 1576-1584.	1.1	44
60	Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy. European Heart Journal, 2021, 42, 3932-3944.	1.0	43
61	Gene family information facilitates variant interpretation and identification of disease-associated genes in neurodevelopmental disorders. Genome Medicine, 2020, 12, 28.	3.6	42
62	Moderate Physical Activity in Healthy Adults Is Associated With Cardiac Remodeling. Circulation: Cardiovascular Imaging, 2016, 9, .	1.3	40
63	Role of Targeted Therapy in Dilated Cardiomyopathy: The Challenging Road Toward a Personalized Approach. Journal of the American Heart Association, 2019, 8, e012514.	1.6	39
64	Disease-specific variant pathogenicity prediction significantly improves variant interpretation in inherited cardiac conditions. Genetics in Medicine, 2021, 23, 69-79.	1.1	39
65	Quality assurance of item writing: During the introduction of multiple choice questions in medicine for high stakes examinations. Medical Teacher, 2009, 31, 238-243.	1.0	38
66	The yield of postmortem genetic testing in sudden death cases with structural findings at autopsy. European Journal of Human Genetics, 2020, 28, 17-22.	1.4	38
67	Associations Between Female Sex, Sarcomere Variants, and Clinical Outcomes in Hypertrophic Cardiomyopathy. Circulation Genomic and Precision Medicine, 2021, 14, e003062.	1.6	38
68	Association of Titin-Truncating Genetic Variants With Life-threatening Cardiac Arrhythmias in Patients With Dilated Cardiomyopathy and Implanted Defibrillators. JAMA Network Open, 2019, 2, e196520.	2.8	33
69	Next Generation Diagnostics in Inherited Arrhythmia Syndromes. Journal of Cardiovascular Translational Research, 2013, 6, 94-103.	1.1	31
70	Identification of an INa-dependent and Ito-mediated proarrhythmic mechanism in cardiomyocytes derived from pluripotent stem cells of a Brugada syndrome patient. Scientific Reports, 2018, 8, 11246.	1.6	31
71	Genomic variant sharing: a position statement. Wellcome Open Research, 2019, 4, 22.	0.9	31
72	Recovery of Cardiac Function in Cardiomyopathy Caused by Titin Truncation. JAMA Cardiology, 2016, 1, 234.	3.0	30

#	Article	IF	CITATIONS
73	Understanding the genetics of adult-onset dilated cardiomyopathy: what a clinician needs to know. European Heart Journal, 2021, 42, 2384-2396.	1.0	28
74	Predictors of left ventricular remodelling in patients with dilated cardiomyopathy – a cardiovascular magnetic resonance study. European Journal of Heart Failure, 2020, 22, 1160-1170.	2.9	27
75	Annotating high-impact 5′untranslated region variants with the UTRannotator. Bioinformatics, 2021, 37, 1171-1173.	1.8	27
76	Ajmaline blocks I Na and I Kr without eliciting differences between Brugada syndrome patient and control human pluripotent stem cell-derived cardiac clusters. Stem Cell Research, 2017, 25, 233-244.	0.3	25
77	European Heart Rhythm Association (<scp>EHRA</scp>)/Heart Rhythm Society (<scp>HRS</scp>)/Asia Pacific Heart Rhythm Society (<scp>APHRS</scp>)/Latin American Heart Rhythm Society (<scp>LAHRS</scp>) Expert Consensus Statement on the state of genetic testing for cardiac diseases. Iournal of Arrhythmia, 2022, 38, 491-553.	0.5	24
78	Precision Phenotyping of Dilated Cardiomyopathy Using Multidimensional Data. Journal of the American College of Cardiology, 2022, 79, 2219-2232.	1.2	24
79	Titin truncating mutations: A rare cause of dilated cardiomyopathy in the young. Progress in Pediatric Cardiology, 2016, 40, 41-45.	0.2	23
80	Bayesian models for syndrome- and gene-specific probabilities of novel variant pathogenicity. Genome Medicine, 2015, 7, 5.	3.6	22
81	Diagnostic yield of hypertrophic cardiomyopathy in first-degree relatives of decedents with idiopathic left ventricular hypertrophy. Europace, 2020, 22, 632-642.	0.7	20
82	Histiocytoid cardiomyopathy and microphthalmia with linear skin defects syndrome: phenotypes linked by truncating variants in <i>NDUFB11</i> . Journal of Physical Education and Sports Management, 2017, 3, a001271.	0.5	19
83	ClinVar data parsing. Wellcome Open Research, 2017, 2, 33.	0.9	19
84	Genetic Studies of Hypertrophic Cardiomyopathy in Singaporeans Identify Variants in <i>TNNI3</i> and <i>TNNT2</i> That Are Common in Chinese Patients. Circulation Genomic and Precision Medicine, 2020, 13, 424-434.	1.6	18
85	Titin Circular RNAs Create a Back-Splice Motif Essential for SRSF10 Splicing. Circulation, 2021, 143, 1502-1512.	1.6	18
86	Clinical impact of re-evaluating genes and variants implicated in dilated cardiomyopathy. Genetics in Medicine, 2021, 23, 2186-2193.	1.1	17
87	Correspondence on "ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG)―byÂMiller etÂal. Genetics in Medicine, 2022, 24, 744-746.	1.1	17
88	Using High-Resolution Variant Frequencies Empowers Clinical Genome Interpretation and Enables Investigation of Genetic Architecture. American Journal of Human Genetics, 2019, 104, 187-190.	2.6	15
89	<i>ZBTB17</i> (<i>MIZ1</i>) Is Important for the Cardiac Stress Response and a Novel Candidate Gene for Cardiomyopathy and Heart Failure. Circulation: Cardiovascular Genetics, 2015, 8, 643-652.	5.1	12
90	Genetic and environmental determinants of diastolic heart function. , 2022, 1, 361-371.		12

#	Article	IF	CITATIONS
91	Computational prediction of protein subdomain stability in MYBPC3 enables clinical risk stratification in hypertrophic cardiomyopathy and enhances variant interpretation. Genetics in Medicine, 2021, 23, 1281-1287.	1.1	11
92	An assessment of the role of vinculin loss of function variants in inherited cardiomyopathy. Human Mutation, 2020, 41, 1577-1587.	1.1	10
93	Prognostic Significance of Nonischemic Myocardial Fibrosis in Patients WithÂNormal LV Volumes and Ejection-Fraction. JACC: Cardiovascular Imaging, 2021, 14, 2353-2365.	2.3	10
94	Integrative genomics in cardiovascular medicine. Cardiovascular Research, 2013, 97, 623-630.	1.8	9
95	Next-generation sequencing using microfluidic PCR enrichment for molecular autopsy. BMC Cardiovascular Disorders, 2019, 19, 174.	0.7	7
96	Improving the Understanding of Genetic Variants in Rare Disease With Large-scale Reference Populations. JAMA - Journal of the American Medical Association, 2019, 322, 1305.	3.8	7
97	Founder Mutation in N Terminus of Cardiac Troponin I Causes Malignant Hypertrophic Cardiomyopathy. Circulation Genomic and Precision Medicine, 2020, 13, 444-452.	1.6	7
98	Genomic variant sharing: a position statement. Wellcome Open Research, 0, 4, 22.	0.9	7
99	Moderate excess alcohol consumption and adverse cardiac remodelling in dilated cardiomyopathy. Heart, 2022, 108, 619-625.	1.2	6
100	Exposure to Elevated Nitrogen Dioxide Concentrations and Cardiac Remodeling in Patients With Dilated Cardiomyopathy. Journal of Cardiac Failure, 2022, 28, 924-934.	0.7	6
101	The Egyptian Collaborative Cardiac Genomics (ECCO-GEN) Project: defining a healthy volunteer cohort. Npj Genomic Medicine, 2020, 5, 46.	1.7	5
102	Harmonizing the Collection of Clinical Data on Genetic Testing Requisition Forms to Enhance Variant Interpretation in Hypertrophic Cardiomyopathy (HCM). Journal of Molecular Diagnostics, 2021, 23, 589-598.	1.2	5
103	Quantifying prediction of pathogenicity for within-codon concordance (PM5) using 7541 functional classifications of BRCA1 and MSH2 missense variants. Genetics in Medicine, 2022, 24, 552-563.	1.1	5
104	Quantifying evidence toward pathogenicity for rare phenotypes: The case of succinate dehydrogenase genes, SDHB and SDHD. Genetics in Medicine, 2022, 24, 41-50.	1.1	5
105	Response by Ho et al to Letter Regarding Article, "Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)― Circulation, 2019, 139, 1559-1560.	1.6	4
106	New Variant With a Previously Unrecognized Mechanism of Pathogenicity in Hypertrophic Cardiomyopathy. Circulation, 2021, 144, 754-757.	1.6	4
107	NECTAR: a database of codon-centric missense variant annotations. Nucleic Acids Research, 2014, 42, D1013-D1019.	6.5	3
108	Direct and indirect effect of the COVID-19 pandemic on patients with cardiomyopathy. Open Heart, 2022, 9, e001918.	0.9	3

#	Article	lF	CITATIONS
109	Republished review: Next generation sequencing for clinical diagnostics and personalised medicine: implications for the next generation cardiologist. Postgraduate Medical Journal, 2012, 88, 234-239.	0.9	2
110	Effect of taurine administration on symptoms, severity, or clinical outcome of dilated cardiomyopathy and heart failure in humans: a systematic review. Wellcome Open Research, 0, 7, 9.	0.9	2
111	50â€Incremental diagnostic value of cardiovascular magnetic resonance in young adult survivors of sudden cardiac arrest. Heart, 2017, 103, A39-A39.	1.2	1
112	121â€Re-evaluating the genetic contribution of monogenic dilated cardiomyopathy. , 2019, , .		1
113	What Is the Risk of Sudden Cardiac Arrest in Inherited Cardiac Conditions?. Journal of the American College of Cardiology, 2020, 75, 2708-2710.	1.2	1
114	Effect of taurine administration on symptoms, severity, or clinical outcome of dilated cardiomyopathy and heart failure in humans: a systematic review. Wellcome Open Research, 0, 7, 9.	0.9	1
115	Effect of taurine administration on symptoms, severity, or clinical outcome of dilated cardiomyopathy and heart failure in humans: a systematic review. Wellcome Open Research, 0, 7, 9.	0.9	1
116	127â€Relationship between plasma concentrations of b-type natriuretic peptide and exercise capacity in hypertrophic cardiomyopathy. Heart, 2017, 103, A96-A97.	1.2	0
117	5â€Defining the effects of genetic variation using machine learning analysis of CMRS: a study in hypertrophic cardiomyopathy and in a healthy population 2018		0